FDA Approves Direct Biologics to Proceed with a Landmark Phase 3 Acute Respiratory Distress Syndrome (ARDS) Trial AUSTIN, Texas, April 21, 2022 Direct Biologics, a… Read More »FDA Approves Direct Biologics to Proceed with a Landmark Phase 3 Acute Respiratory Distress Syndrome (ARDS) Trial
FDA Grants Direct Biologics Regenerative Medicine Advanced Therapy (RMAT) Designation for the use of ExoFlo in COVID-19 Related ARDS AUSTIN, Texas, April 12, 2022 Direct… Read More »FDA Grants Direct Biologics Regenerative Medicine Advanced Therapy (RMAT) Designation for the use of ExoFlo in COVID-19 Related ARDS
Direct Biologics Reveals Successful Outcomes from EXIT COVID-19 Phase II Clinical Trial AUSTIN, Texas, April 6, 2022 Direct Biologics, a regenerative biotechnology company with a… Read More »Direct Biologics Reveals Successful Outcomes from EXIT COVID-19 Phase II Clinical Trial